Nanoemulsão tópica de canabidiol e quercetina sobre inflamação e barreira cutânea em dermatite atópica experimental

Adjanna Leite; Rivaldo Miranda; Alison Hideo Jolo Silva; Antonio José Alves; Valdemiro Amaro da Silva Junior

doi:10.1590/SciELOPreprints.16713

##article.authors##

Adjanna Leite Federal Rural University of Pernambuco https://orcid.org/0000-0002-6684-9846
- Conceptualization
- Formal Analysis
- Methodology
- Writing – Original Draft Preparation
- Writing – Review & Editing
- Investigation
- Resources
- Visualization
- Validation
- Project Administration
- Data Curation
Rivaldo Miranda Federal University of Pernambuco https://orcid.org/0009-0009-0812-6461
- Methodology
- Resources
- Investigation
- Formal Analysis
- Writing – Review & Editing
Alison Hideo Jolo Silva Federal Rural University of Pernambuco https://orcid.org/0000-0003-4140-7336
- Software
- Validation
- Writing – Review & Editing
- Formal Analysis
- Data Curation
- Methodology
Antonio José Alves Federal University of Pernambuco https://orcid.org/0000-0002-2668-6931
- Supervision
- Validation
- Writing – Review & Editing
Valdemiro Amaro da Silva Junior Federal Rural University of Pernambuco https://orcid.org/0000-0002-1894-7337
- Validation
- Supervision
- Formal Analysis

DOI:

https://doi.org/10.1590/SciELOPreprints.16713

Keywords:

atopic dermatitis, cannabidiol, nanoemulsion, skin barrier, quercetin

Abstract

Atopic dermatitis is a chronic inflammatory skin disease characterized by epidermal barrier dysfunction and dysregulated immune responses. This study developed and evaluated a topical nanoemulsion containing cannabidiol (CBD) and quercetin (QU) in Pentravan® using an experimental rat model. Twenty-eight Wistar rats were allocated into four groups (n=7): Pentravan® (GI), Pentravan® + 1% CBD (GII), Pentravan® + 1% QU (GIII), and Pentravan® + 1% CBD + 1% QU (GIV). Formulations were characterized by particle size, polydispersity index, and zeta potential. Efficacy was assessed by clinical-dermatological examination, adapted SCORAD, thermography, transepidermal water loss (TEWL), and histopathological analysis over four weeks. The CBD+QU group showed more pronounced reduction of inflammatory parameters, lower dermal infiltrate, spongiosis, and exocytosis compared to isolated treatments. The topical association of CBD and QU in Pentravan® nanoemulsion showed therapeutic potential for experimental atopic dermatitis.